SCHEMBL2732258

SCHEMBL2732258

O=C=NCc1cc(Cl)cc(Cl)c1

nearest known ligand 0.38

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.38
IDO1 P14902 2/20 0.38
TACR1 P25103 2/20 0.33
DAO P14920 1/20 0.32
GRIN1 Q05586 1/20 0.32
GRIN2B Q13224 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.31
TPMT P51580 1/20 0.31
TP53 P04637 1/20 0.31
CYP3A4 P08684 1/20 0.31
MAPK1 P28482 1/20 0.30
TDP1 Q9NUW8 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL199862 0.85 CYP3A4 (0.32) TSHRCYP3A4
SCHEMBL18345630 0.80 FFAR1 (0.33) CYP3A4
SCHEMBL151739 0.79 MIF (0.44) IDO1L3MBTL1
SCHEMBL3924560 0.79 HTR3E (0.52) IDO1GRIN2BCYP3A4
SCHEMBL30483624 0.79 HTR3E (0.52) IDO1GRIN2BCYP3A4
SCHEMBL459297 0.76 PGK1 (0.40) GRIN2BCYP3A4
SCHEMBL27705400 0.76 PGK1 (0.35) TSHRGRIN2BTPMTCYP3A4
SCHEMBL28709411 0.76 MIF (0.52) TSHRIDO1GRIN1GRIN2BCYP3A4
SCHEMBL459983 0.76
SCHEMBL29384068 0.76

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117285890-A Preparation method of formaldehyde-free environment-friendly flame-retardant plywood 南宁市匠心鸣居建筑材料有限公司 2023-12-26 CN claimed
CN-115724772-B Compound with urea structure, and preparation and application thereof 云南大学 2024-08-02 CN disclosed
CN-116970011-B Sulfonamide compound containing ureido structure and preparation method and application thereof 沈阳药科大学 2024-05-10 CN disclosed
CN-117980066-A Method for producing stationary phase for column chromatography 株式会社大赛璐 2024-05-03 CN disclosed
CN-116082195-B Pleuromutilin urea compounds, and preparation method and application thereof 中国医学科学院药物研究所 2024-03-26 CN disclosed
CN-117343032-A Method for preparing amide compound based on photocatalytic isocyanate 中国科学技术大学 2024-01-05 CN disclosed
CN-114634449-B Preparation method of 3- (3, 5-dichlorophenyl) -2, 4-imidazolidinedione 北京颖泰嘉和生物科技股份有限公司 2023-12-26 CN disclosed
CN-114634449-B Preparation method of 3- (3, 5-dichlorophenyl) -2, 4-imidazolidinedione 北京颖泰嘉和生物科技股份有限公司 2023-12-26 CN disclosed
CN-116966885-A Bonding type polysaccharide chiral stationary phase and preparation method and application thereof 中国科学院化学研究所 2023-10-31 CN disclosed
CN-116970011-A Sulfonamide compound containing ureido structure and preparation method and application thereof 沈阳药科大学 2023-10-31 CN disclosed
US-9273028-B2 Heterocyclic tyrosine kinase inhibitors BIOGEN MA INC. (US) 2016-03-01 US disclosed
US-9273028-B2 Heterocyclic tyrosine kinase inhibitors BIOGEN MA INC. (US) 2016-03-01 US disclosed
US-9273028-B2 Heterocyclic tyrosine kinase inhibitors BIOGEN MA INC. (US) 2016-03-01 US disclosed
US-20130345192-A1 HETEROCYCLIC TYROSINE KINASE INHIBITORS SUNESIS PHARMACEUTICALS, INC. (US) 2013-12-26 US disclosed
EP-2632898-A1 HETEROCYCLIC TYROSINE KINASE INHIBITORS Biogen Idec MA Inc. (US) 2013-09-04 EP disclosed
WO-2012058645-A1 HETEROCYCLIC TYROSINE KINASE INHIBITORS BIOGEN IDEC MA INC. (US) 2012-05-03 WO disclosed
WO-2012058645-A1 HETEROCYCLIC TYROSINE KINASE INHIBITORS BIOGEN IDEC MA INC. (US) 2012-05-03 WO disclosed
US-6417218-B1 HT3 ANTAGONIST OR ANTIHISTAMINES NOVO NORDISK A/S (DK) 2002-07-09 US disclosed
EP-1147092-A1 SUBSTITUTED IMIDAZOLES, THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 2001-10-24 EP disclosed
WO-2000042023-A1 SUBSTITUTED IMIDAZOLES, THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 2000-07-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130345192-A1 HETEROCYCLIC TYROSINE KINASE INHIBITORS TEC, ABL1, LCK TSHR 3511/4885IDO1 1537/4885TACR1 4423/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.